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Can We Become Victims of Our Own
Success?
T
he last 5 years seem to have marked
atransitioninthehistoryofdiabetes
care. Whereas for two decades we
have preached the importance of good
glycemic control to manage the risk of di-
abetes-associated complications, the
truth of the matter is that rarely did pa-
tients with diabetes achieve target A1C
levels 7%. As reported in Diabetes Care
in 20008 in an analysis of the National
HealthandNutritionExaminationSurvey
(NHANES)dataset,theoddsratio(OR)of
people with diagnosed diabetes achieving
an A1C 7% had increased 2.5-fold be-
tween 1999–2000 and 2003–2004. Most
impressively, the average A1C among
those treated with diet alone over the
same interval had decreased from 7.04 to
6.07%, with 89.7% having an A1C 7%
(1). Undoubtedly, this improvement is
due in part to improved comprehensive
management of diabetes as a result of
better access to diabetes education and
nutrition services, the rapid advances in
the pharmacotherapy for diabetes, and
better screening and diagnosis of diabe-
tes. As reported in Diabetes Care in 2009
using the NHANES dataset, though the
prevalence of diabetes continues to rise,
it is clearly being recognized more fre-
quently (2).
In this issue, Cheng et al. (3) present
another masterful analysis of the
NHANESdataset.Thestudyexaminesthe
relationship between two measures of
glycemia(A1Candfastingplasmaglucose
[FPG]) and the prevalence of retinopathy
in 1,066 individuals 40 years of age or
older in the 2005–2006 NHANES data-
set.Afterexcludingthoseindividualswho
were using hypoglycemic medications,
the glycemic levels above which the prev-
alence of retinopathy “took off” were A1C
5.5% and FPG 7.0 mmol/l (126 mg/dl).
Furthermore, A1C was a better predictor
of retinopathy risk than FPG, determined
by receiver operator curve analysis. The
authors suggest that this analysis has
implications for diagnostic thresholds
for diabetes. This is a critical issue be-
cause there has been an increasing call
over many years for a diagnostic strategy
using A1C, and a recent recommenda-
tion suggests that an A1C of 6.5% is an
appropriate diagnostic threshold based
in large part on a similar analysis of
28,000 subjects from nine countries in
the Evaluation of Screening and Early
Detection Strategies for Type 2 Diabetes
and Impaired Glucose Tolerance study
(DETECT-2) pooling project (4).
The authors point out that other
datasets have suggested other diagnos-
tic thresholds of A1C for diabetes. The
discussion is excellent, and a variety of
potentially confounding factors are ex-
plored,primarilydifferencesinA1Cassay
used and differences in techniques for as-
sessing and deﬁning retinopathy. Fortu-
nately, at least in future studies, A1C
assays have been standardized interna-
tionallytoamuchgreaterextentthanglu-
cose assays. The ideal study design to
examinehowbesttomakethediagnosis
of diabetes would be a prospective co-
hort study in which the rates of incident
retinopathy could be examined over
time in a large population of nondia-
betic individuals.
The current report is relatively small,
increasing the potential for a spurious re-
sult. The population does reﬂect the pop-
ulation of the U.S. and therefore is
arguably most appropriate for determin-
ing diagnostic strategies for our uniquely
multiethnic and overweight population.
The current study uses a very sensitive
deﬁnition of retinopathy that would tend
to be less speciﬁc and therefore perhaps
suggestsalowerthresholdthanalesssen-
sitive, more speciﬁc deﬁnition.
However, I wonder if the fundamen-
tal reason that the current report suggests
such a low threshold for the development
of retinopathy is that the data are exclu-
sively collected in 2005–2006 and in-
clude data from people with known
abnormalities of glucose metabolism—
people with both diabetes and other re-
lated abnormalities such as impaired
fasting glucose, impaired glucose toler-
ance, and metabolic syndrome who have
been counseled to make lifestyle changes
to reduce glycemia.
Thus, the A1C data for 2005–2006 in
the NHANES study may reﬂect not the
peak A1C of a lifetime of gradually in-
creasing insulin resistance and declining
insulin secretion but a new lower level
attained as a result of our success in man-
aging risk in the overweight with abnor-
malities in glucose, lipids, or blood
pressure.Thisissuggestedbytheremark-
ably low level of A1C among people with
diagnosed diabetes treated with lifestyle
management in 2003–2004 presented
above.IftheaverageA1Camonglifestyle-
treated people with diabetes was 6%,
almost certainly they had a higher A1C at
some point in their life. Great analytical
caution is necessary to avoid the nearly
inevitable pitfalls of examining a popula-
tion with diagnosed diabetes to decide
what the appropriate cut point for the di-
agnosis should be based on the presence
of a complication that clearly developed
at some time prior to enrollment in the
study. With improving screening and
control, we may otherwise fall victims to
our own success in an endless spiral of
more intensive medicalization.
Whether abnormalities of glycemia
arediagnosedwithA1Cinthefutureatan
A1C of 5.5%, as implied in the current
report, 6.0% (5) or 6.5% (4) will directly
affect the lives of many tens of millions of
peopleintheU.S.aloneandperhapshun-
dreds of millions of people worldwide.
Those at lower risk because of more nor-
mal baseline glycemia theoretically are at
lower risk of complications, and thus the
potential beneﬁt from their identiﬁcation
will come at a higher price both person-
ally and societally. These decisions will
haveanenormousandforeseeableimpact
on health care systems and costs.
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